Post-earnings recap
Reported
Thu, Jul 27, 2017
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
100%
Boston Scientific's earnings report shows a slight beat on EPS, indicating better-than-expected profitability. However, the stock fell by 1.35%, likely due to a lack of revenue data and no guidance updates, which may have left investors uncertain about future performance. The company's focus on innovation suggests potential for growth, but market challenges remain a concern.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.32 | N/A | +2.84% |
| Revenue | N/A | N/A | N/A |
Overall, management remains positive about the company's direction despite some market challenges. They emphasized their commitment to innovation and growth.
Management highlighted ongoing product innovation as a key driver for future growth.
They acknowledged challenges in certain markets but expressed confidence in their long-term strategy.
—
Est. EPS
—
Est. Rev
—
Impl. Move
—